Japanese investment giant SoftBank’s Vision Fund 2 has spearheaded a $100 million funding round in Biofourmis, a digital therapeutics startup. The investment round also witnessed participation from the startup’s existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital, and EDBI.

Biofourmis, headquartered in Singapore, operates globally across the US and Asia Pacific. It was established in 2015 by Kuldeep Singh Rajput, a native of Bengaluru, who is an alumnus of IIT Madras and pursued further studies at the National University of Singapore.

“Our vision is to use digital medicine to empower patients, clinicians, and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy,” stated Rajput.

The startup specializes in providing healthcare solutions driven by artificial intelligence and machine learning. With the recent investment, Biofourmis intends to deepen its commitment to healthcare offerings with new verticals – Biofourmis Therapeutics and Biofourmis Health. The former will provide digital therapeutics solutions with a “beyond the pill” approach, while the latter will concentrate on remote patient management, utilizing predictive analysis to mitigate medical crises.

“Biofourmis Health’s ‘home hospital’ initiative leverages the company’s AI-based remote monitoring to lower healthcare costs—through reductions in length of stay, readmissions, and emergency department visits, among other measures,” the company explained.

Reports suggest that with the latest funding round, the company’s valuation has tripled from $250 million to $750 million. Previously, Biofourmis had raised $35 million in a Series B round in May 2019.